Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GAIA-Aβ
- Development stage
- Preclinical
- Lead developer
- Illimis Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
GAIA-Aβ is a chimeric fusion protein drug developed as a novel immunotherapeutic agent for Alzheimer's disease. It consists of a single-chain variable fragment of an amyloid-β (Aβ)-targeting monoclonal antibody fused to a truncated receptor-binding domain of growth arrest-specific 6 (Gas6). This construct harnesses TAM (TYRO3, AXL, and MERTK) receptor-dependent phagocytosis to induce clearance of Aβ plaques by both microglia and astrocytes, without triggering Fc receptor-mediated inflammatory responses commonly seen with conventional Aβ antibodies. The dual phagocytic activation and anti-inflammatory mechanism distinguishes GAIA-Aβ from standard antibody drugs, reducing side effects such as cerebral edema and microhemorrhage (ARIA) associated with antibody-mediated clearance in Alzheimer's disease[1][2]. Developed by Illimis Therapeutics, GAIA-Aβ is designed to overcome safety and efficacy limitations of traditional antibody therapeutics in neurodegenerative and immune diseases[2].
- Brand names
- GAIA-Aβ
- Other names
- αAβ-Gas6
02
Targets
AXL (AXL receptor tyrosine kinase)Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on GAIA-Aβ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GAIA-Aβ.